mAbxience Research S.L.

mAbxience Research S.L., based in Madrid, Spain, is a biotechnology company. mAbxience is a vertically integrated biopharmaceutical company that develops biosimilars and operates an independent contract development and manufacturing organisation (CDMO) platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in melanoma and non-small-cell lung cancer. The largest, NCT06687369 (A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)), plans to enrol 726 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.